|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.244 SEK | -2.05% |
|
+9.31% | +34.63% |
| 22/05 | Intervacc AB Completes Successful Evaluation of Us Strain of Strangles Pathogen Ahead of Clinical Trials | CI |
| 15/05 | Sweden's Intervacc Elects New Chair | MT |
Company Valuation: Intervacc AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,669 | 1,313 | 479.4 | 88.61 | 314.9 | 432.8 | - | - |
| Change | - | -50.81% | -63.48% | -81.52% | 255.38% | 37.45% | - | - |
| Enterprise Value (EV) 1 | 2,553 | 1,267 | 391.2 | 54.31 | 154 | 339.8 | 369.8 | 378.8 |
| Change | - | -50.36% | -69.13% | -86.12% | 183.58% | 120.64% | 8.83% | 2.43% |
| P/E | -90.2x | -20.3x | -3.75x | -1.17x | -3.42x | -5.77x | -5.77x | -7.7x |
| PBR | 8.66x | 5.25x | 2.01x | 0.55x | 1x | 2.23x | 2.15x | - |
| PEG | - | -0x | -0.1x | 0x | 0x | 0.3x | - | 0.3x |
| Capitalization / Revenue | 509x | 136x | 59.8x | 7.52x | 15.7x | 24.5x | 14.4x | 3.58x |
| EV / Revenue | 487x | 131x | 48.8x | 4.61x | 7.67x | 19.2x | 12.3x | 3.13x |
| EV / EBITDA | -110x | -29.1x | -5.67x | -0.92x | -3.27x | -5.36x | -5.61x | -10.4x |
| EV / EBIT | -86.9x | -19.7x | -4.18x | -0.7x | -1.84x | -4.13x | -4.36x | -6.84x |
| EV / FCF | -53.3x | -16.7x | -8.16x | -1.01x | -2.3x | -4.72x | -4.93x | -6.01x |
| FCF Yield | -1.88% | -5.99% | -12.3% | -99.2% | -43.4% | -21.2% | -20.3% | -16.6% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.59 | -1.28 | -1.69 | -1 | -0.27 | -0.22 | -0.22 | -0.165 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 5.241 | 9.684 | 8.015 | 11.79 | 20.09 | 17.7 | 30.05 | 121 |
| EBITDA 1 | -23.24 | -43.56 | -68.98 | -58.75 | -47.09 | -63.45 | -65.95 | -36.5 |
| EBIT 1 | -29.39 | -64.41 | -93.58 | -77.28 | -83.5 | -82.35 | -84.85 | -55.4 |
| Net income 1 | -29.38 | -64.16 | -102.9 | -75.52 | -80.82 | -80.8 | -83.65 | -66 |
| Net Debt 1 | -115.5 | -45.52 | -88.2 | -34.3 | -160.9 | -93 | -63 | -54 |
| Reference price 2 | 53.200 | 26.000 | 6.330 | 1.170 | 0.924 | 1.270 | 1.270 | 1.270 |
| Nbr of stocks (in thousands) | 50,160 | 50,491 | 75,736 | 75,736 | 340,813 | 340,813 | - | - |
| Announcement Date | 18/2/22 | 17/2/23 | 16/2/24 | 13/2/25 | 17/2/26 | - | - | - |
1SEK in Million2SEK
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5.77x | 19.2x | -5.36x | - | 44.5M | |
| 33.11x | 8.21x | 25.31x | 0.04% | 56.19B | |
| 20.62x | 6.35x | 13.89x | 1.54% | 54.83B | |
| -18.25x | 4.33x | -7.59x | -.--% | 23.04B | |
| -41x | 13.02x | -38.35x | -.--% | 22.7B | |
| 25.46x | 4.98x | 13.19x | -.--% | 20.23B | |
| 24.92x | 4.83x | 15.71x | -.--% | 17.83B | |
| -786.44x | 37.38x | -4208.26x | -.--% | 15.65B | |
| 45.88x | 18.59x | 47.88x | 0.08% | 15.24B | |
| 17.56x | 5.09x | 11.87x | -.--% | 14.03B | |
| Average | -68.39x | 12.20x | -413.17x | 0.19% | 23.98B | |
| Weighted average by Cap. | -36.55x | 9.73x | -263.94x | 0.37% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- IVACC Stock
- Valuation Intervacc AB
Select your edition
All financial news and data tailored to specific country editions
